The long rang objective of this project is to investigate the origin, differentiation, and function of NK cells. The working hypothesis, derived from their research and that of others, is that NK cells represent a relatively homogenous discrete cell type, with various defensive and regulatory activities, including but not limited to cell-mediated cytotoxicity and that the effectiveness and specificity of NK cells in vivo depend on a complex network of interactions with humoral factors and other cellular types. Although much progress has been made recently on the characterization of NK cells, their inhibitory and stimulatory receptors, and their ability to produce cytokines, the exact physiological roles of NK cells at the interface of innate and adaptive immunity, and the mechanisms of their activation in response to pathological insults still await a better understanding. Dr. Trinchieri hypothesized that NK cells, in addition to their direct role in innate resistance, play an role in shaping the type of adaptive immune responses and that the cytokines important in regulatory NK cell activity, particularly IFN-alpha and IL-12, and the cell types producing them constitute an important backbone in the immunoregulatory cross-talk between the innate resistance and acquired immunity. In order to understand further this immuno-regulatory mechanism, he proposes to investigate: 1) Proliferation, cytokine production and differentiation of NK cells. 2) Characterization and function of C1.7 Ag, a signal transducing receptor on NK cells and a marker of activation of CD8 t cells. 3) The relationship between IFN-alpha producing cells and dendritic cells and the physiological relevance of IFN-alpha in the interaction of dendritic cells with NK cells and T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA020833-24
Application #
6150010
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Finerty, John F
Project Start
1985-04-01
Project End
2004-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
24
Fiscal Year
2000
Total Cost
$467,516
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brando, Clara; Mukhopadhyay, Sunil; Kovacs, Eniko et al. (2005) Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol 78:359-71
Gomez, German G; Read, Susana B; Gerschenson, Lazaro E et al. (2004) Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro Oncol 6:83-95
Wysocka, Maria; Zaki, Mohamed H; French, Lars E et al. (2002) Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 100:3287-94
Wysocka, M; Robertson, S; Riemann, H et al. (2001) IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol 166:7504-13
Trinchieri, G; Scott, P (1999) Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 238:57-78
Marshall, J D; Chehimi, J; Gri, G et al. (1999) The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Blood 94:1003-11
Kubin, M Z; Parshley, D L; Din, W et al. (1999) Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur J Immunol 29:3466-77
Fox, F E; Kubin, M; Cassin, M et al. (1999) Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 19:407-15
Schwarz, A; Grabbe, S; Mahnke, K et al. (1998) Interleukin 12 breaks ultraviolet light induced immunosuppression by affecting CD8+ rather than CD4+ T cells. J Invest Dermatol 110:272-6
Karp, C L; Wysocka, M; Ma, X et al. (1998) Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur J Immunol 28:3128-36

Showing the most recent 10 out of 107 publications